Menu
Search
|

Menu

Close
X

Rockwell Medical Inc RMTI.OQ (NASDAQ Stock Exchange Global Market)

3.08 USD
+0.17 (+5.84%)
As of Sep 13
Previous Close 2.91
Open 2.91
Volume 78,831
3m Avg Volume 113,332
Today’s High 3.10
Today’s Low 2.89
52 Week High 6.88
52 Week Low 2.19
Shares Outstanding (mil) 63.84
Market Capitalization (mil) 199.17
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY19
16
FY18
63
FY17
57
FY16
53
EPS (USD)
FY19
-0.152
FY18
-0.607
FY17
-0.507
FY16
-0.391
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
3.11
7.90
Price to Book (MRQ)
vs sector
8.84
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
-94.65
12.69
Return on Equity (TTM)
vs sector
-147.58
17.13

EXECUTIVE LEADERSHIP

Benjamin Wolin
Independent Chairman of the Board, Since 2018
Salary: --
Bonus: --
Stuart Paul
President, Chief Executive Officer, Director, Since 2018
Salary: $184,615.00
Bonus: $300,000.00
Angus Smith
Chief Financial Officer, Since 2018
Salary: $20,000.00
Bonus: $125,000.00
Jim McCarthy
Senior Vice President - Corporate and Business Development, Since 2018
Salary: --
Bonus: --
Paul McGarry
Principal Accounting Officer, Vice President, Corporate Controller, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

30142 S Wixom Rd
WIXOM   MI   48393-3440

Phone: +1248.9609009

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company's drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.

SPONSORED STORIES